{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["67(8)"],"submitter":["Sachpekidis C"],"funding":["Deutsche Krebshilfe"],"pubmed_abstract":["<h4>Background</h4>Immunotherapy has raised the issue of appropriate treatment response evaluation, due to the unique mechanism of action of the immunotherapeutic agents. Aim of this analysis is to evaluate the potential role of quantitative analysis of 2-deoxy-2-(<sup>18</sup>F)fluoro-D-glucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) data in monitoring of patients with metastatic melanoma undergoing ipilimumab therapy.<h4>Methods</h4>25 patients with unresectable metastatic melanoma underwent dynamic PET/CT (dPET/CT) of the thorax and upper abdomen as well as static, whole body PET/CT with <sup>18</sup>F-FDG before the start of ipilimumab treatment (baseline PET/CT), after two cycles of treatment (interim PET/CT) and at the end of treatment after fou"],"journal":["Cancer immunology, immunotherapy : CII"],"pagination":["1261-1270"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028129"],"repository":["biostudies-literature"],"pubmed_title":["Longitudinal studies of the <sup>18</sup>F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT."],"pmcid":["PMC11028129"],"pubmed_authors":["Larribere L","Dimitrakopoulou-Strauss A","Winkler JK","Hassel JC","Haberkorn U","Anwar H","Sachpekidis C","Kopp-Schneider A"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal studies of the <sup>18</sup>F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.","description":"<h4>Background</h4>Immunotherapy has raised the issue of appropriate treatment response evaluation, due to the unique mechanism of action of the immunotherapeutic agents. Aim of this analysis is to evaluate the potential role of quantitative analysis of 2-deoxy-2-(<sup>18</sup>F)fluoro-D-glucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) data in monitoring of patients with metastatic melanoma undergoing ipilimumab therapy.<h4>Methods</h4>25 patients with unresectable metastatic melanoma underwent dynamic PET/CT (dPET/CT) of the thorax and upper abdomen as well as static, whole body PET/CT with <sup>18</sup>F-FDG before the start of ipilimumab treatment (baseline PET/CT), after two cycles of treatment (interim PET/CT) and at the end of treatment after fou","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Aug","modification":"2025-04-22T20:42:36.378Z","creation":"2025-04-06T03:17:41.434Z"},"accession":"S-EPMC11028129","cross_references":{"pubmed":["29872898"],"doi":["10.1007/s00262-018-2183-3"]}}